Intellia Therapeutics
NTLA
285 hedge funds and large institutions have $2.51B invested in Intellia Therapeutics in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 117 increasing their positions, 88 reducing their positions, and 41 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 88
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.33% less ownership
Funds ownership: 95.34% → 95.02% (-0.33%)
3% less capital invested
Capital invested by funds: $2.6B → $2.51B (-$89.6M)
6% less call options, than puts
Call options by funds: $21.7M | Put options by funds: $23M
10% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 41
3% less funds holding
Funds holding: 293 → 285 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$54.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$47.4M |
| 3 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$31.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.3M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$15.4M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$13.6M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$11.8M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.2M |
NTLA Hedge Fund Activity: Q1 2024 in Review
285 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2024, worth a combined $2.51B — down 3.4% from $2.6B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of NTLA and 37 opened new positions — a net loss of 4 holders — while 88 trimmed existing stakes and 117 added.
The largest buyer was Deep Track Capital, adding an estimated $54.5M. The largest seller was Marshall Wace, cutting an estimated $15.4M.
- 285 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2024, down from 293 in Q4 2023.
- Funds reported $2.51B of Intellia Therapeutics stock for Q1 2024, down 3.4% quarter-over-quarter.
- 37 funds opened new Intellia Therapeutics positions in Q1 2024 and 41 closed out, a net change of -4 holders.
- The largest Intellia Therapeutics buyer in Q1 2024 was Deep Track Capital, an estimated $54.5M added.
- The largest Intellia Therapeutics seller in Q1 2024 was Marshall Wace, an estimated $15.4M sold.
Based on aggregated 13F filings for Q1 2024.